Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers
- PMID: 8299669
- DOI: 10.1007/BF00265954
Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers
Abstract
Gamma-hydroxybutyric acid (GHB) is effective in treatment of the alcohol and opiate withdrawal syndromes. Its absorption and disposition kinetics have been studied in 8 healthy male volunteers following oral administration of single doses of 12.5, 25 and 50 mg kg-1. The AUC increased disproportionately with the dose and so the apparent oral clearance decreased significantly as the dose was increased, whereas the terminal half-life and mean residence time increased. The peak plasma concentrations normalised to the lowest dose fell significantly with increasing doses, whilst the corresponding peak times increased. These findings suggest that both the oral absorption and the elimination of GHB are capacity-limited processes. GHB did not bind to significant extent to plasma proteins over the therapeutic concentration range. The pharmacokinetic parameters in healthy volunteers were not significantly different from those previously observed in alcohol-dependent patients with compensated alcoholic liver disease.
Similar articles
-
Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses.Br J Clin Pharmacol. 1992 Sep;34(3):231-5. doi: 10.1111/j.1365-2125.1992.tb04129.x. Br J Clin Pharmacol. 1992. PMID: 1389947 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.Br J Clin Pharmacol. 2016 May;81(5):980-8. doi: 10.1111/bcp.12863. Epub 2016 Feb 25. Br J Clin Pharmacol. 2016. PMID: 26659543 Free PMC article. Clinical Trial.
-
The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.J Clin Pharmacol. 2004 Mar;44(3):253-7. doi: 10.1177/0091270003262795. J Clin Pharmacol. 2004. PMID: 14973300 Clinical Trial.
-
The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.Clin Toxicol (Phila). 2012 Jul;50(6):458-70. doi: 10.3109/15563650.2012.702218. Clin Toxicol (Phila). 2012. PMID: 22746383 Review.
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
Cited by
-
Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons.Psychopharmacology (Berl). 2005 Jul;180(2):342-51. doi: 10.1007/s00213-005-2165-y. Epub 2005 Mar 1. Psychopharmacology (Berl). 2005. PMID: 15739078
-
Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid.AAPS J. 2011 Jun;13(2):240-54. doi: 10.1208/s12248-011-9264-y. Epub 2011 Mar 9. AAPS J. 2011. PMID: 21387146 Free PMC article.
-
Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study.J Clin Toxicol. 2011 Nov 10;1(2):1000105. doi: 10.4172/2161-0495.1000105. J Clin Toxicol. 2011. PMID: 24772380 Free PMC article.
-
Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.Arh Hig Rada Toksikol. 2020 Mar 1;71(1):19-26. doi: 10.2478/aiht-2020-71-3314. Arh Hig Rada Toksikol. 2020. PMID: 32597141 Free PMC article. Review.
-
Monocarboxylate transporter (MCT) mediates the transport of gamma-hydroxybutyrate in human kidney HK-2 cells.Pharm Res. 2007 Jun;24(6):1067-78. doi: 10.1007/s11095-006-9228-6. Epub 2007 Mar 22. Pharm Res. 2007. PMID: 17377745
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical